Davey B. Daniel

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• National implementation of electronic patient-reported outcomes (ePROs) for remote symptom monitoring in oncology: The OncoPRO initiative.

  Journal of Clinical Oncology · 2026-05-27

• PP01.66: Frequency, Treatment Patterns and Clinical Outcomes of STK11, KEAP1 and KRAS Among De Novo Metastatic Non-Small Cell Lung Cancer Patients: A Retrospective Chart Review of the OneOncology Network Electronic Medical Records

  Journal of Thoracic Oncology · 2026-05-01

• Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial

  Journal of Thoracic Oncology · 2026-03-01

• Impact of community recruitment and inclusion initiatives on enrollment in the biomarker-driven MyTACTIC trial

  Future Oncology · 2025-12-15

• Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial

  JTO Clinical and Research Reports · 2025-10-30

• Longer follow-up for survival and safety from the EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel in patients (pts) with metastatic non-small cell lung cancer (mNSCLC).

  Journal of Clinical Oncology · 2025-05-28 · 2 citations

• A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment

  The Oncologist · 2025-05-01 · 2 citations

• Genomic lookback: Identifying patients who are eligible for newly approved targeted therapies based on historic biomarker findings.

  JCO Oncology Practice · 2024-09-30 · 1 citations

• Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

  New England Journal of Medicine · 2024-09-13 · 276 citations

• LBA81 Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial

  Annals of Oncology · 2024-09-01 · 13 citations